title: The risk of adenoid hypertrophy in children with allergic rhinitis.
abstract: BACKGROUND
  Adenoid hypertrophy (AH) may cause significant morbidity in children but its relationship to allergic rhinitis (AR) has not been studied.
  
  
  OBJECTIVE
  To determine the risk factor of AH in patients with AR.
  
  
  METHODS
  We studied 315 children (ages 1 to 18 years) who had AH and AR. We compared them with 315 age-matched controls who had AR alone. To identify risk factors, they were divided into four groups according to age and clinical parameters, including the prevalence of otitis media, sinusitis, lower respiratory infection, exposure to smoking, sleep disorders, use of antihistamine/decongestants, and results of allergy skin testing.
  
  
  RESULTS
  The prevalence of upper or lower respiratory infections was higher in the group with AR and AH, but not in all age groups. A high prevalence of exposure to smoking and skin test reactivity against house dust mites were found in both groups. However, the prevalence of positive reactivity to molds was significantly higher in the group with AH and AR (P ranged from 0.013 to <0.0001 and the relative risk ranged from 1.609 to 2.375). Further, the risk of AH was positively correlated with number of skin test reactivity to mold spores (P ranged from 0.0035 to 0.0001). Positive skin test reactivity to animal danders or seasonal allergens failed to predict the risk of AH.
  
  
  CONCLUSIONS
  Sensitivity to mold allergens is an important risk factor for AH in children with AR; therefore, early prevention of exposure to molds may help reduce occurrence of AH.
authors.affiliation: Department of Pediatrics, University of Florida, Gainesville, USA. huangsw@peds.ufl.edu
authors.forename: S W
authors.initials: SW
authors.lastname: Huang
authors.forename: C
authors.initials: C
authors.lastname: Giannoni
mesh_terms: D000234:Adenoids / Q000000981:diagnostic imaging; D000293:Adolescent; D000485:Allergens; D002648:Child; D002675:Child, Preschool; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006984:Hypertrophy / Q000209:etiology; D007223:Infant; D008206:Lymphatic Diseases / Q000000981:diagnostic imaging / Q000209:etiology*; D014663:Nasal Decongestants / Q000627:therapeutic use; D010033:Otitis Media / Q000175:diagnosis; D011859:Radiography; D012141:Respiratory Tract Infections / Q000175:diagnosis; D012189:Retrospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications*; D012307:Risk Factors; D012852:Sinusitis / Q000175:diagnosis; D012882:Skin Tests; D012893:Sleep Wake Disorders / Q000175:diagnosis; D013172:Spores, Fungal / Q000276:immunology; D014028:Tobacco Smoke Pollution
chemical_list: D000485:Allergens; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D014028:Tobacco Smoke Pollution